Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.
Giovanni
G
Barosi
Elisabetta
E
Gattoni
Paola
P
Guglielmelli
Rita
R
Campanelli
Fabio
F
Facchetti
Simona
S
Fisogni
Judith
J
Goldberg
Roberto
R
Marchioli
Ronald
R
Hoffman
Alessandro M
AM
Vannucchi
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000098:blood supply / Q000473:pathology; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012306:Risk; D016879:Salvage Therapy; D013921:Thrombocytopenia / Q000139:chemically induced; D017211:Treatment Failure; D055815:Young Adult
D020533:Angiogenesis Inhibitors; D001897:Boronic Acids; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib